Cardiovascular Outcomes With Finerenone in Patients With CKD and Diabetes

Cardiovascular Outcomes With Finerenone in Patients With CKD and Diabetes

Mediation by UACR of kidney and cv outcomes in T2D and CKDSee more

Mediation by UACR of kidney and cv outcomes in T2D and CKD

George Bakris, MD | Use of Finerenone in Patients with Diabetes Who Have Kidney DiseaseSee more

George Bakris, MD | Use of Finerenone in Patients with Diabetes Who Have Kidney Disease

Nonsteroidal mineralocorticoid receptor antagonists & cardiorenal outcomes in chronic kidney diseaseSee more

Nonsteroidal mineralocorticoid receptor antagonists & cardiorenal outcomes in chronic kidney disease

Nephrology Grand Rounds - April 28, 2022See more

Nephrology Grand Rounds - April 28, 2022

Finerenone, a non-steroidal MRASee more

Finerenone, a non-steroidal MRA

Finerenone in Patients with Diabetes and CKDSee more

Finerenone in Patients with Diabetes and CKD

FIDELIO DKD ResultsSee more

FIDELIO DKD Results

Professor David Wheeler - Renoprotective effects of SGLT2 inhibitorsSee more

Professor David Wheeler - Renoprotective effects of SGLT2 inhibitors

Effects of canagliflozin versus finerenone on cardiorenal outcomesSee more

Effects of canagliflozin versus finerenone on cardiorenal outcomes

Dr Rajiv Agarwal Discusses Finerenone, Results of FIDELIO-DKDSee more

Dr Rajiv Agarwal Discusses Finerenone, Results of FIDELIO-DKD

FIDELIO-DKD AND FIGARO-DKD TRIAL SUMMARY - FINRENONESee more

FIDELIO-DKD AND FIGARO-DKD TRIAL SUMMARY - FINRENONE

News